This is a corrigendum to Clin Pharmacokinet. 2022 Apr 4 An Integral Pharmacokinetic
Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients …

Abstract Background and Objectives Although dose optimization studies have been
performed for piperacillin and tazobactam separately, a combined integral analysis is not yet …

The pharmacokinetics of piperacillin, tazobactam and its M1 metabolite were studied in
patients with various degrees of renal impairment after single and multiple intravenous …

Study Objective To evaluate the pharmacokinetic and pharmacodynamic profiles of
piperacillin‐tazobactam administered as a 4‐hour infusion in critically ill patients undergoing …

Objectives To evaluate the pharmacokinetics of piperacillin/tazobactam in critically ill
patients undergoing continuous renal replacement therapy (CRRT) and to assess the …

Tazobactam is a new derivative of penicillinic acid sulfone, which functions as an
irreversible inhibitor of many β‐lactamases. The disposition of tazobactam M1 metabolite …

What is known and objective Timely and appropriate dosing of antibiotics is essential for the
treatment of bacterial sepsis. Critically ill patients treated with continuous kidney …

Tazobactam is an irreversible inhibitor of many β‐lactamases. In combination with
piperacillin, tazobactam exhibits synergy against many β‐lactamase? producing bacteria …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

When piperacillin/tazobactam has been used to treat hospitalized patients with serious
infections, including nosocomial pneumonia caused by Pseudomonas aeruginosa, it has …